The four members of the human CYP3A subfamily play important roles in the clearance of xenobiotics, hormones, and environmental compounds. Many SNPs at the CYP3A locus have been characterized, with several showing large allele frequency differences across populations. In addition to the effects of CYP3A SNPs on drug metabolism, recent studies have highlighted the potential for CYP3A variation in susceptibility to several common phenotypes, including hypertension and cancer. We previously showed that the CYP3A4 and CYP3A5 genes have a strong haplotype structure at varying frequencies across ethnic groups. Here, we extend our re-sequencing survey to the remaining CYP3A genes in the same cluster, CYP3A7 and CYP3A43. Our study identified a large number of SNPs in coding and conserved noncoding sequences, several of which are common. The combined data set allows us to investigate patterns of sequence variation and linkage disequilibrium at the entire CYP3A locus for use in future association studies.
Introduction
The human CYP3A gene subfamily, located on chromosome 7, spans approximately 220 kb and consists of four drug-metabolizing enzyme genes, CYP3A43, CYP3A4, CYP3A7, and CYP3A5. CYP3A enzymes are involved in the oxidative metabolism of a wide range of substrates, including clinical drugs such as erythromycin 1 and ketoconazole, 2 as well as environmental compounds 3 and endogenous targets such as cortisol, estradiol, and testosterone. 4 The number and structural diversity of CYP3A targets may be due in part to the flexibility of the enzyme's relatively large active site. 5 In particular, CYP3A4, abundantly expressed in liver and small intestine, is predicted to play a role in the metabolism and clearance of at least 50% of therapeutic drugs, steroids, and environmental compounds. 6, 7 Although there is some overlap in substrate specificity, the four members of the CYP3A subfamily demonstrate substantial regulatory differences with regard to level and pattern of expression, as well as developmental timing. CYP3A4 and CYP3A5 are the dominant adult forms, demonstrating the highest levels of expression in liver and intestine and playing a large role in clinical drug metabolism. 8 CYP3A7 is predominantly a fetal enzyme, with high levels of expression in fetal liver and intestine, tapering off after birth in most. 9 CYP3A7 plays an important role in the metabolism of endogenous substrates, such as testosterone and dehydroepiandrosterone, as well as potentially toxic compounds such as retinoic acid. 10, 11 The role of CYP3A7 in the metabolism and clearance of these and many exogenous substrates to which the fetus is exposed, as well as large inter-individual differences in fetal CYP3A7 expression level 12 have led to the suggestion that differences in CYP3A7 expression and/or activity could contribute to inter-individual differences in embryonic toxicity and teratogenicity. 13 Since CYP3A43 is expressed at very low levels in several tissues, including liver, prostate, and testis, 14 it is not believed to play a substantial role in drug metabolism and has not been investigated as extensively as other members of the subfamily. However, the conversion of testosterone to less active forms by CYP3A43 raises the possibility that genetic variation at this locus could affect levels of circulating testosterone and possibly contribute to prostate cancer risk. Consistent with this idea, an association was recently reported between a CYP3A43 coding SNP and prostate cancer risk in African Americans. 15 A number of sequence variants at the CYP3A locus have been identified, but few of them have been definitively associated with alterations in mRNA or protein levels and/or CYP3A function. The CYP3A4*1B allele, originally reported to be associated with advanced clinical grade of prostate tumors, 16 is a common SNP located in the 5 0 flanking region. A number of nonsynonymous (ns) SNPs have been reported for CYP3A4, but most occur at low frequency. 17 Of the few variants reported for CYP3A5, at least two result in nonfunctional proteins and are found at frequencies of 10% or greater only among African Americans (CYP3A5*6 and CYP3A5*7). 18, 19 The CYP3A5*3 allele, which is found at high frequency in some populations, introduces a cryptic splice site and ultimately leads to a frameshift mutation and a truncated protein. 18 A few ns polymorphisms have been detected in both CYP3A7 and CYP3A43, some of which have been suggested to affect function. 13, 15 In particular, the CYP3A7*2 allele, which falls in exon 11, has been shown to result in increased enzymatic activity, 13 and an SNP at CYP3A43 (Pro340Ala) has been associated with prostate cancer risk. 15 However, no systematic survey of variation has been performed at these genes, either individually or within the context of the entire CYP3A locus.
We previously surveyed sequence variation in conserved coding and noncoding regions of the CYP3A4 and CYP3A5 genes in three ethnically diverse samples. 20 This study revealed strong levels of linkage disequilibrium (LD) and the presence of a relatively homogenous class of haplotypes, spanning both genes, at high frequency in the non-African populations. It was hypothesized that the observed haplotype structure and large differences in allele frequencies were due to the action of positive natural selection on a variant influencing sodium homeostasis and, possibly, risk to salt-sensitive hypertension.
These findings raise the possibility that this striking haplotype structure and inter-ethnic differences in allele frequencies extend to the remaining members of the CYP3A locus, that is, CYP3A7 (which lies between CYP3A4 and CYP3A5) and CYP3A43 (at the 5 0 end of the locus). We therefore performed a re-sequencing survey of the CYP3A7 and CYP3A43 genes in a subset of the population samples from our previous study, 20 using a comparative genomicsbased approach to select conserved coding and noncoding sequences to be surveyed. These regions represent candidate functional elements, potentially harboring polymorphisms that may contribute to phenotypic variation in CYP3A-mediated xenobiotic clearance. This approach was combined with computational predictions of clusters of liverenriched transcription factor binding sites to identify high probability clusters conserved between humans and at least two other species. In order to elucidate the patterns of LD across the entire locus, the results of this survey were analyzed together with those previously obtained at the CYP3A4 and CYP3A5 genes for the same set of 48 individuals. Throughout this paper, the analyses use the newly generated data for the CYP3A7 and CYP3A43 genes as well as a subset of the previously published data for the CYP3A4 and CYP3A5 genes. This larger data set thus provides the first comprehensive survey of CYP3A coding and noncoding variation in ethnically diverse populations and forms the foundation for designing association and replication studies of inter-individual and inter-ethnic variation in drug response.
Results

Re-sequencing survey design and results
In order to identify highly conserved noncoding regions for inclusion in the re-sequencing survey, mammalian CYP3A genes (from Papio anubis, Canis familiaris, Rattus norvegicus, and Mus musculus) and surrounding genomic sequences were aligned to each of the four human CYP3A genes using MultiPipMaker. 21 The extent of sequence identity and the regions included in the re-sequencing survey are shown in Figure 1 . Computational prediction of clusters of liverenriched transcription factor binding sites identified six clusters that were included in the survey: three at CYP3A4, described by Thompson et al., 20 two at CYP3A7, and one at CYP3A43. All of these regions were conserved between human and at least two other species and are indicated along the X axes of the MultiPipMaker plots.
The entire surveyed sequence, including all four CYP3A genes, spans 220 kb. In total, over 68 kb of sequence was surveyed, including over 6 kb of coding sequence and 62 kb of conserved noncoding sequence (CNS). The extent of surveyed sequence for each gene is shown in Table 1 . Sequence divergence between human and chimpanzee is relatively low for CYP3A43 and CYP3A7 (0.88 and 1%, respectively), as well as for CYP3A4 and CYP3A5 (0.86 and 0.66%) compared to the genome-wide average of 1.24%. 22 We identified a total of 224 polymorphic sites, including 13 biallelic and three multiallelic indels. Two hundred and four polymorphic sites were located in noncoding sequence and 20 in coding sequence, including eight synonymous (s) and 11 ns substitutions. While all ns SNPs in CYP3A4 or CYP3A5 had an allele frequency lower than 2% in the total population, one ns SNP at CYP3A43 was found at 18% (Pro340Ala, nucleotide position (nt. pos.) 73084) and one ns SNP at CYP3A7 was found at 27% (Thr409Arg, nt. pos. 224011). A single nucleotide deletion in CYP3A43, which causes an amino-acid substitution and ultimately results in a frameshift mutation, 23 was found at 3% allele frequency.
Only one singleton ns SNP (nt. pos. 280388) was found to reside in a predicted substrate recognition site. 24 To predict the functional significance of amino-acid variants identified in this study, we analyzed our data using Samples are a subset of those used in a previous study of CYP3A4 and CYP3A5. 20 Here, the summary statistics for these two genes and their percentile rank relative to the Seattle SNP genes were re-calculated for the sample subset used in this analysis. SIFT (Sorting Intolerant From Tolerant). 25 SIFT searches for similar sequences to generate an alignment and then calculates probability scores for altered function based on the amino acids appearing at each position in the alignment. The default threshold for declaring functional significance is 0.05, 25 although evidence exists for increasing the threshold to 0.10. For example, the UGT1A1*6 (G71R) variant, with a SIFT score of 0.10, has been experimentally shown to alter serum bilirubin levels. 26, 27 The results of this analysis for the observed CYP3A variants are shown in Table 3 . Our results suggest that the majority of ns SNPs at the CYP3A locus are likely to affect protein function.
Of the six regions containing predicted clusters of transcription factor binding sites that also are conserved across species, five contain SNPs that alter at least one putative liver-enriched transcription factor binding site predicted by Match 1.0 (data not shown); most of these SNPs occur at low frequency. Only one SNP identified in this survey falls in one of the transcription factor binding sites predicted within a cluster; this SNP (nt. pos. 137569) is a singleton in the African-American sample, and disrupts a predicted HNF-1 binding site.
To assess the probability that a variant affects an evolutionarily conserved position, we inferred the ancestral allele of each polymorphic site by comparing it to the orthologous position in the chimpanzee genome. The inferred ancestral allele at 35 out of 204 (17%) polymorphic sites occurring in CNSs was identical to that found in the same position in the remaining four species (baboon, dog, rat, and mouse). The species used in this comparison sample three deep lineages in the mammalian phylogeny (i.e. primates, carnivores, and rodents) and span a total evolutionary time of greater than 300 million years. 28 Thus, identical nucleotide positions across these three lineages are likely to be functionally constrained and polymorphic variants at these positions may affect the gene function. A list of polymorphic sites that fall in positions conserved across the three lineages included in the study is found in Table 2 . At CYP3A7, five SNPs in strong LD with one another (with greater than 10% minor allele frequency (MAF)) fall in positions where the ancestral allele is conserved across all species included in the alignment.
Nucleotide variation and the allele frequency spectrum Summary statistics of the polymorphism data are shown in Table 1 , and a visual representation of the sequence data, in the form of inferred haplotypes, is shown in Figure 2 . Levels of polymorphism across the four genes are summarized by nucleotide diversity (p), based on the mean number of pairwise differences between sequences, and Watterson's estimator of the population mutation rate parameter y (y W ), based on the number of polymorphic sites and sample size. 29 The frequency spectrum of polymorphic sites is captured by Tajima's D (D). 30 An excess of rare variants is indicated by a negative D value, while a positive value signals an excess of intermediate frequency variants.
In order to assess whether the patterns of polymorphism at the CYP3A locus are unusual, we compared the values of the summary statistics to the corresponding values for the genes in the University of Washington-Fred Hutchinson Cancer Research Center Variation Discovery Resource (Seattle SNPs), a project focused on genes involved in inflammatory response. The European and African-American samples used in our study are the same as those used in the Seattle SNPs project, making possible a direct comparison across loci, but the Asian data could not be compared as it is not available from the Seattle SNPs data set. Our results for the polymorphism levels (p and y W ), D, and y W divided by human-chimpanzee divergence (to account for our resequencing regions having been selected due to strong evolutionary constraints) all were compared to the distribution of these values from 159 genes in the Seattle SNP data set. 20 Several striking features are observed at the CYP3A7 and CYP3A43 genes. D values are strongly positive in African Americans, but markedly negative in the European sample, indicating an excess of intermediate frequency variants and rare variants in the African-American and European samples, respectively.
These findings are consistent with the F ST results in Figure 2 . The F ST statistic summarizes allele frequency differentiation between samples, and a genome-wide survey of 25 549 autosomal SNPs revealed an average worldwide F ST value of 0.123. 31 Our estimates of F ST values for each site between the African-American sample and each non-African sample confirmed that many sites at the CYP3A locus are characterized by large differences in allele frequency across populations. Our F ST findings are consistent with the observed large differences in allele frequency between populations and strong haplotype structure across samples, and might be expected if a specific haplotype class was driven quickly to high frequency by natural selection in one of the populations.
To investigate this possibility, we used the haplotype test. 32 Briefly, given the number of segregating sites in a population sample, coalescent simulations under neutrality are performed to estimate the probability that a haplotype subset of a given size has as few or fewer polymorphic sites as in the observed haplotype distribution. Because it was previously suggested that the CYP3A5*3 allele (nt. pos. 260167) was the target of natural selection, we focused on this site for the purpose of this analysis. In the Asian sample, the most common class of haplotypes defined by the CYP3A5*3 allele accounts for 84% of the chromosomes surveyed; the results of the haplotype test across the entire CYP3A cluster suggest that the probability of our data is very low (P ¼ 0.03). The haplotype structure of the European sample is slightly more complex, where the haplotype defined by CYP3A5*3 is found at extremely high frequency (97%), but two recombinant haplotypes are also observed. We therefore performed the haplotype test on a large subset of this common class of haplotypes (also accounting for 84% of the chromosomes surveyed) spanning the entire locus, and again, the probability of our data is very low (P ¼ 0.012).
The haplotype test was not significant for the AfricanAmerican sample.
Given the strong LD across this genomic region (see below), the possibility that the true or an additional target of selection is located outside the CYP3A5 gene cannot be excluded. The unusual patterns of frequency spectrum and polymorphism levels at CYP3A7 coupled with the presence of a common amino-acid variant (CYP3A7*2, nt. pos. 224011) with a likely effect on function suggest that this gene (in addition or as an alternative to CYP3A5) experienced positive natural selection.
LD and haplotype tag SNPs
A number of polymorphisms across the two dominant adult CYP3A genes, CYP3A4 and CYP3A5, were previously identified. 17 However, the LD relationships among SNPs in the four CYP3A genes, which are closely related both physically and functionally, are unknown. The survey of a common set of population samples allows the investigation of the patterns of LD and haplotype structure across the entire CYP3A gene cluster. The pattern of pairwise LD across the CYP3A cluster is illustrated in Supplementary Figure 1 . The data are summarized by |D 0 |, and only variants with MAF greater than 9% in each population were included in the analysis. The most extensive LD in all populations exists at CYP3A7 and continues in the direction of CYP3A5. In the European and Asian samples, strong LD extends also through the CYP3A4 surveyed segment, while in all populations LD decays substantially between CYP3A4 and CYP3A43.
The strong LD pattern coupled with the large differences in allele frequencies between populations presents a number of challenges for the design of association studies of CYP3A variation and specific phenotypes and for the interpretation of their results. To investigate the relationship between the unusual haplotype and geographic structure of CYP3A variation and the design of association studies, we selected tag SNPs in each population separately. LdSelect was used to identify the maximally informative set of tag SNPs that capture genetic diversity across the four CYP3A genes. 33 LdSelect uses a threshold r 2 value, a measure of LD, to select tag SNPs. We analyzed our data with an MAF cutoff of 9% and r 2 thresholds of 0.64 and a more stringent value, 0.8; given the extensive LD in this region for the two nonAfrican populations, roughly the same number of tag SNPs were selected with both threshold values (Table 3) . To capture genetic diversity in all three populations, a total of 31 (r 2 ¼ 0.64) or 49 (r 2 ¼ 0.8) tag SNPs are required. The lower number of tag SNPs selected for the non-African samples is likely to reflect the lower genetic diversity in these populations relative to the African-American sample.
Discussion
The results presented in our recent survey of CYP3A4 and CYP3A5, 20 together with the new data presented here, comprise the first comprehensive survey of sequence variation at the human CYP3A locus. We performed largescale genomic sequence comparisons of the CYP3A locus across five mammalian species in order to identify CNS segments within and between the four human genes, which are candidates for functional elements involved in CYP3A expression. Our survey of sequence variation at coding and CNSs identified a genomic region with strong LD, as well as a number of coding and noncoding variants that may have Refers to the minimum number of tag SNPs required to cover sequence variation across three populations.
functional effects. In the non-African populations in particular, the CYP3A locus is characterized by strong LD and a large number of high-frequency derived alleles, suggesting that a homogeneous class of haplotypes has quickly risen to high frequency. This pattern of variation is likely due to an advantageous variant, such as the CYP3A5*3 allele, or another variant in LD with it. As a result of this striking pattern of variation, there is a large difference in the number of tag SNPs necessary to capture the haplotype structure in populations of African and non-African descent.
The extended LD observed at the CYP3A locus and the observed pattern of variation are remarkable and need to be taken into account when designing association studies. The large differences in allele frequency across populations and the strong LD extending across 150 kb in this region complicate both survey design and the interpretation of results. Identifying and understanding the haplotype structure and pattern of LD in the study population is important in determining the success of association studies; if unaccounted for, differences across populations can lead to inconsistencies across studies and a lack of repeatability. For example, variation in CYP3A expression and/or activity has been proposed to contribute to breast cancer risk, but association studies so far have yielded conflicting results. CYP3A4 catalyzes the hydroxylation of estrogen to two active metabolites, at least one of which has been associated with mammary tumors in rodents 34 and humans. 35, 36 In addition, CYP3A enzymes are involved in the activation of numerous environmental pro-carcinogens into their active carcinogenic forms, making a role for CYP3A variation in cancer susceptibility biologically plausible. 37 However, the results of association studies of CYP3A variation and breast cancer risk are inconsistent. The CYP3A4*1B allele has been associated with early onset of menarche, a risk factor for breast cancer, 38 but in a case-control study of Caucasian women from Australia, the CYP3A4*1B allele was not associated with breast cancer risk. 39 Other studies have reported an association between breast cancer risk and urinary 6b-hydroxycortisol:cortisol ratios, with the ratio indicating CYP3A4 activity. 40 Overall, the contribution of genetic variation at the CYP3A locus to breast cancer susceptibility remains inconclusive and will require thorough studies taking into account the large differences in allele frequency and haplotype structure across populations.
In a study by Ng and Henikoff, 25 a large experimental data set was used to test the ability of SIFT and BLOSUM62 to predict deleterious amino-acid changes; overall, the difference in total predication accuracy between the two programs was 14%, with SIFT outperforming BLOSUM62. 41 In addition, Leabman et al. 42 found that SIFT scores were among the best predictors of function in a large survey of variation in human membrane transporter genes. The majority of the ns SNPs identified in this study were found at low frequency (o5%) and predicted to affect protein function by SIFT. The two common ns SNPs (nt. pos. 73084 and 224011) are predicted to affect protein function, with significance thresholds less than 0.03, and both have been recently reported and characterized. 13, 15 The predictions for the CYP3A7*2 variant (nt. pos. 224011) are in line with the results of a recent functional study, where it was associated with increased enzymatic activity in vitro. 13 The interpretation of these results is not always straightforward; for example, the M445T SNP in CYP3A4 (nt. pos. 172170), which falls in a highly conserved position and is predicted to be strongly deleterious (SIFT score ¼ 0.00), does not result in a significant alteration of CYP3A4 expression or catalytic activity in functional studies. 43, 44 In one study, however, individuals with the variant T allele did have lower LDL cholesterol (although the sample size was small), suggesting that the metabolism of certain steroid sex hormones, which are believed to influence cholesterol levels, may be altered in individuals with this polymorphism. 45 Alternatively, it is possible that this variant could alter protein function in another way, such as by affecting stability.
The large number of intronic and intergenic SNPs identified in this survey highlights the potential importance of noncoding variation on gene expression and, ultimately, function, especially at a locus where most coding variants are found at relatively low frequency and in a heterozygous state. The additional information gained by identifying and surveying regions predicted to contain clusters of transcription factor binding sites will be of particular importance for future functional studies of these regions.
Of the six regions predicted to contain a cluster of liverenriched transcription factor binding sites with high probability, one of the regions at the CYP3A4 locus has since been demonstrated to contain functional sequences and harbor population variation affecting constitutive expression. 46 Our approach allowed us to narrow the search from almost 200 kb of noncoding sequence to six regions with increased probability of containing functional elements. The combination of comparative genomics with searches for clusters of transcription factor binding sites served to identify a noncoding region of the CYP3A cluster with important effects on gene expression.
Our survey of the CYP3A cluster in several human population samples was designed in part to assess the potential signature of natural selection, as the role of drugmetabolizing enzyme genes at the interface of an organism and its environment makes them a likely target for natural selection. Our approach makes use of theoretical expectations, based on the neutral equilibrium model, as well as empirical expectations, based on comparisons to a large data set (Seattle SNPs). Since the precise evolutionary history of humans cannot be inferred reliably, the comparison of our results to an empirical distribution of a large set of loci surveyed in the same samples can be used to assess deviation; the variation in such a distribution would reflect the variance associated with the history of each population. Given that the genes included in the Seattle SNP data set are believed to be implicated in inflammatory disease and are therefore likely to have evolved under different selections models, the variation present in this data set may be greater than that expected if all genes had evolved neutrally and our comparisons to this data set may therefore be conservative. It should be noted, however, that the sample sizes differ between our data set and that of Seattle SNPs (32 chromosomes per population vs 46-48, respectively), with the smaller sizes in our study possibly resulting in a greater variance of the distribution.
Although our analysis of the complete CYP3A data set is still consistent with the action of natural selection at the CYP3A5*1/*3 allele, we cannot rule out the possibility that a variant elsewhere in the CYP3A cluster (but in strong LD with CYP3A5 variation) is the true or an additional target of selection. For example, the derived allele at nt. pos. 224011 (CYP3A7*2) has recently been shown to result in increased CYP3A7 enzymatic activity, 13 and is generally found in strong LD with the CYP3A5*1 allele (nt. pos. 260167). The result is a CYP3A haplotype common in African-American populations that is characterized by expression of CYP3A5 and increased enzymatic activity of CYP3A7, which may have important functional effects in the fetus. The results of the haplotype test at CYP3A7 in the European and Han samples (defined by CYP3A7*1, nt. pos. 224011) are both significant (P ¼ 0.004 and 0.005, respectively), while the same test in the African-American sample is not significant. Therefore, although we observe a strong signal of selection in the two non-African populations, we are unable to discriminate between CYP3A5 and CYP3A7 as the true target.
In summary, our data represent the first comprehensive survey of patterns of sequence variation at the human CYP3A locus. Our study reveals large differences in allele frequency and haplotype structure across populations and correspondingly different sets of haplotype tag SNPs necessary to capture information regarding genetic variation. These observations lay the foundation for the design of definitive association studies between CYP3A variation and a variety of common phenotypes including drug response and breast and prostate cancer.
Materials and methods
Library screening and BAC clone sequencing Universal oligonucleotide probes (overgos) were designed based on an alignment of human, mouse, and rat CYP3A coding sequence 47 and were used to screen BAC libraries for the mouse (RPCI-23), rat (RPCI-32), dog (RPCI-81), and olive baboon (RPCI-41). Four clones identified by hybridization were sequenced using the random shotgun approach 48 as described previously using the Amersham ET dye-labeled terminators (see Roe laboratory web site for details) and were assigned the following GenBank accession numbers: AC113434 (RP23-456N12), AC133490 (RP32-162C1), AC141417 (RP41-443B7), and AC131027 (RP81-168J21).
Comparative analysis and re-sequencing study design All BAC clones were aligned to the four human CYP3A genes using MultiPipMaker, a pairwise alignment program capable of handling unordered sequences. Repetitive elements were masked using RepeatMasker. Mouse and rat sequence information included additional clones from public databases. Because the ancestral relationships between these genes cannot be determined unambiguously, the sequence alignment included multiple genes from each nonhuman species. Human reference sequences were analyzed with ClusterBuster in order to identify potential clusters of binding sites for the following liver-enriched transcription factors: HNF1a, HNF4, PXR, CAR, OCT-1, PPAR, RXR, CEBP, HNF3b, HNF4/COUP-TF. Regions containing clusters predicted with high probability and conserved between humans and at least two other species were included in the resequencing study (as illustrated in Figure 1 ).
Population samples
Human population samples used in the re-sequencing survey included 16 European individuals from the CEPH families, 16 individuals from the Human Variation Panel of African Americans, and 16 individuals from the Human Variation Panel of Han People of Los Angeles. These samples are a subset of those used in our previous study of CYP3A4 and CYP3A5. 20 All DNA samples are unrelated and were obtained from the Coriell Cell Repository, and the AfricanAmerican and Han samples are a subset of those used in the Perlegen study. 49 Sample information can be found on the PharmGKB web site. The orthologous regions were sequenced in one western chimpanzee (Pan troglodytes verus) for use as an outgroup. This study was approved by the Institutional Review Board of the University of Chicago.
PCR amplification and sequencing PCR and sequencing primers were designed based on GenBank accession number NG_000004; all nucleotide positions in this article are numbered according to this sequence. Primer sequences are available on the PharmGKB web site. PCR products were cleaned with exonuclease I and shrimp alkaline phosphatase (United States Biochemicals). Dye-terminator sequencing was performed with ABI Big Dye Terminator v. 3.1 Cycle Sequencing kit and products were analyzed on an ABI 3700 or 3730 automated sequencer (Applied Biosystems). The Phred-Phrap-Consed package (Polyphred version 4.0.5) was used to assemble and analyze all sequences. 50 At CYP3A7 and CYP3A43, the chimpanzee sequence was obtained from Ensembl (CYP3A7:CHIMP1: 6:100653028: 100790728:1, September 2004; CYP3A43: AC146392). All putative polymorphisms were visually inspected and individual genotypes were confirmed using Consed. In addition to PharmGKB, sample information, primer sequences, polymorphism data, and outgroup sequences are available on the Di Rienzo lab web site.
Data analysis
Summary statistics of DNA sequence variation were calculated using SLIDER and MAXDIP. |D 0 | and r 2 were calculated from diploid data, according to the maximum likelihood method. 51 Haplotypes were inferred using PHASE2 52 in each population sample separately.
F ST , a measure of allele frequency variation among samples, was calculated between the African-American and each non-African sample for each polymorphic site. 53 Coalescent simulations for the haplotype test were per-formed assuming values of 4Nr estimated from the data for each population sample. For all tests, gene conversion was assumed to occur twice as often as cross-over, and the mean conversion tract length was 500 bp.
Selection of the maximally informative set of SNPs (haplotype tag SNPs) for association studies was performed using LdSelect, 33 with r 2 thresholds of 0.64 and 0.80 and an MAF cutoff of 9% per population sample.
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